19 FebAfraxis to take part in NIHs Therapeutics for Rare and Neglected Disease Program Afraxis.

‘TRND collaborates with researchers and businesses with an aim of translating promising molecules into potential fresh drugs for rare and neglected illnesses,’ said NHGRI’s John McKew PhD, Chief of TRND’s Therapeutic Development Branch. ‘That is a difficult phase of drug advancement associated with high failure rates for just about any molecule. The outcome could be uncertain.’.. Afraxis to take part in NIH’s Therapeutics for Rare and Neglected Disease Program Afraxis, a San Diego-based biotechnology business developing drugs to take care of rare genetic diseases through the modulation of p21-activated kinase , announced today that it’s been selected to participate in the National Institutes of Health’s Therapeutics for Rare and Neglected Disease Program.What we found can be that if teenagers are performing on working memory tasks that tap into executive attention poorly, they are more likely to engage in impulsive drug-use behaviors. The results suggest new approaches for early intervention since weaknesses in executive working often underlie self-control problems in children as young as 3 years previous, she said. A grouped family environment strong in structured routines and cognitive-stimulation could improve working memory skills, she said. For teenagers, interventions could be built around actions that encourage social competence and problem solving skills in conjunction with cognition-building efforts to increase self-control and functioning memory. The latter allows people to temporarily store, organize and manipulate mental details and is vital for evaluating implications of decisions.